Direct oral anticoagulants (DOACs) are small molecule inhibitors of the coagulation
proteases thrombin and factor Xa that demonstrate comparable efficacy to warfarin for …

Background: The Direct Oral Anticoagulants (DOACs) represent a new generation of
antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or …

The direct oral anticoagulants (DOACs), now including dabigatran, apixaban and
rivaroxaban, have given clinicians alternative options to low molecular weight heparins …

Although the landscape of anticoagulation therapy is evolving, vitamin K antagonists (VKAs)
such as warfarin remain an anticoagulant of choice for many clinicians and their patients …

Non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin and heparins
in several clinical situations. With varying modes of action, the effects of NOACs on thrombus …

Objectives: To reduce interlaboratory variation and bias in international normalized ratio
(INR) results, as used to monitor patients receiving vitamin K antagonist therapy, including …

Background Cerebral small vessel disease is a progressive disease of the brain's deep
perforating blood vessels. It is usually diagnosed based on lesions seen on brain imaging …

Welcome to a very special issue of Seminars in Thrombosis & Hemostasis. This issue, on
the topic of “Anticoagulant therapy: present and future,” is guest edited by Job Harenberg, a …

Awards” in honor of Eberhard F. Mammen (► Fig. 1), and in recognition of his contribution to
this field and to the journal that he both founded and steered for over three decades. These …

Hemostasis Awards in honor of Eberhard Mammen (► Fig. 1) and in recognition of his
contribution to this field and to the journal that he both founded and steered for more than …